Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers

Conclusions Combination temsirolimus/metformin was well tolerated with modestly promising effectiveness among this heavily pretreated patient cohort. We recommend a dose of temsirolimus 25 mg weekly and metformin 2000 mg daily for phase II study.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research